These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 6797215)

  • 1. Prevention of infection with protected environment and prophylactic antibiotics in the therapy of acute leukemia.
    Nagao T; Watanabe K; Nozaki H; Komatsuda M; Arimori S
    Nihon Ketsueki Gakkai Zasshi; 1981 Feb; 44(1):78-85. PubMed ID: 6797215
    [No Abstract]   [Full Text] [Related]  

  • 2. Protected environments and prophylactic antibiotics. A prospective controlled study of their utility in the therapy of acute leukemia.
    Levine AS; Siegel SE; Schreiber AD; Hauser J; Preisler H; Goldstein IM; Seidler F; Simon R; Perry S; Bennett JE; Henderson ES
    N Engl J Med; 1973 Mar; 288(10):477-83. PubMed ID: 4630706
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative randomized study of protected environment plus oral antibiotics versus oral antibiotics alone in neutropenic patients.
    Lohner D; Debusscher L; Prévost JM; Klastersky J
    Cancer Treat Rep; 1979 Mar; 63(3):363-8. PubMed ID: 106963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protected environment--prophylactic antibiotic programmes; clinical studies.
    Levine AS
    Clin Haematol; 1976 Jun; 5(2):409-24. PubMed ID: 939058
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of oral antibiotics in protected units environment: clinical effectiveness and role in the emergence of antibiotic-resistant strains.
    Klastersky J; Debusscher L; Weerts D; Daneau D
    Pathol Biol (Paris); 1974 Jan; 22(1):5-12. PubMed ID: 4360753
    [No Abstract]   [Full Text] [Related]  

  • 6. Infection prevention during induction of remission in children with newly diagnosed acute leukemia.
    Roord JJ; Fleer A; Sjamsoedin-Visser EJ; Vreuls R; Hähle K; Stoop JW
    Ann Ist Super Sanita; 1986; 22(3):973-7. PubMed ID: 3103515
    [No Abstract]   [Full Text] [Related]  

  • 7. Experience with protective isolation for infection prevention in the compromised host.
    Nagao T
    Tokai J Exp Clin Med; 1986; 11 Suppl():23-8. PubMed ID: 3132751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of studies on protected environments and prophylactic antibiotics in adult acute leukemia.
    Levine AS; Robinson RA; Hauser JM
    Eur J Cancer (1965); 1975 Aug; 11suppl():57-66. PubMed ID: 815093
    [No Abstract]   [Full Text] [Related]  

  • 9. Preliminary studies of the effectiveness of a patient isolation unit and of prophylactic antibiotics in therapy of acute leukemia.
    Klastersky J; Cappel R; Debusscher L; Lachapelle F
    Acta Clin Belg; 1971; 26(4):191-200. PubMed ID: 5004992
    [No Abstract]   [Full Text] [Related]  

  • 10. Protected environment--prophylactic antibiotic programmes; microbiological studies.
    Bodey GP; Rodriguez V
    Clin Haematol; 1976 Jun; 5(2):395-408. PubMed ID: 780031
    [No Abstract]   [Full Text] [Related]  

  • 11. Protected environment units in the treatment of acute leukemia.
    Preisler HD; Bjornsson S
    Semin Oncol; 1975 Dec; 2(4):369-77. PubMed ID: 824738
    [No Abstract]   [Full Text] [Related]  

  • 12. A controlled clinical trial to evaluate a protected environment and prophylactic antibiotic program in the treatment of adult acute leukemia.
    Freireich EJ; Bodey GP; Rodriguez V; Gehan EA; Smith T; Hester JP; McCredie KB; Rawson RW
    Trans Assoc Am Physicians; 1975; 88():109-19. PubMed ID: 772923
    [No Abstract]   [Full Text] [Related]  

  • 13. Protected environment units for the cancer patient.
    Bodey GP; Watson P; Cooper C; Freireich EJ
    CA Cancer J Clin; 1971; 21(4):215-9. PubMed ID: 4998235
    [No Abstract]   [Full Text] [Related]  

  • 14. [Infection prevention in acute leukemia under protected environment (author's transl)].
    Nagao T; Komatsuda M; Watanabe K; Nozaki H; Yamauchi K; Arimori S
    Rinsho Ketsueki; 1980 Jul; 21(7):961-7. PubMed ID: 7420745
    [No Abstract]   [Full Text] [Related]  

  • 15. [Low-green environment for the overcoming of granulocytopenic stages in leukemia therapy].
    Wendt F; Grüning B; Lenz B; Brittinger G; Linzenmeier G
    Verh Dtsch Ges Inn Med; 1969; 75():916-20. PubMed ID: 4993911
    [No Abstract]   [Full Text] [Related]  

  • 16. [Prevention of infectious complications in patients with myelosuppression by means of isolation and oral administration of non-absorptive antibiotics (evaluation of clinical effectiveness)].
    Baranov AE; Nadezhina NM
    Ter Arkh; 1978; 50(7):38-45. PubMed ID: 213855
    [No Abstract]   [Full Text] [Related]  

  • 17. [Prevention of infection in patients with agranulocytosis through isolation and whole-body decontamination].
    Fopp M; Gasser A; Eigenmann B; Jungi WF; Meuret G; Senn HJ
    Schweiz Med Wochenschr; 1975 Aug; 105(35):1123-5. PubMed ID: 808849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient isolation units for cancer patients treated with chemical immunosuppressive agents.
    Bodey GP
    Transplant Proc; 1973 Sep; 5(3):1279-84. PubMed ID: 4199579
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of acute leukaemia and medullary inhibition in aseptic environment (author's transl)].
    Bláha M; Vanásek J; Mĕrka V; Erichleb M; Splino M; Siroký O; Mazák J; Hrncír Z; Malý J
    Cas Lek Cesk; 1978 Jun; 117(22-23):698-701. PubMed ID: 98234
    [No Abstract]   [Full Text] [Related]  

  • 20. Infections in cancer patients on a protected environment-prophylactic antibiotic program.
    Bodey GP; Rodriguez V
    Am J Med; 1975 Oct; 59(4):497-504. PubMed ID: 810021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.